Records containing: NASH - Nonalcoholic Steatohepatitis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-02-20A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
-
CLINICAL_TRIALS study record update · 2023-12-28Role of a Wheat-based Diet in NASH (NASH-ATI)
-
CLINICAL_TRIALS study record update · 2023-11-07Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement
-
CLINICAL_TRIALS study record update · 2023-10-05A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function
-
CLINICAL_TRIALS study record update · 2023-09-25A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-08-29A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
-
CLINICAL_TRIALS study record update · 2023-08-22Non-invasive Rapid Assessment of Non-alcoholic Fatty Liver Disease (NAFLD) Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1)
-
CLINICAL_TRIALS study record update · 2023-08-21Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2023-08-16Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health (ADLH)"
-
CLINICAL_TRIALS study record update · 2023-07-25Vitamin E for NASH Treatment in HIV Infected Individuals
-
CLINICAL_TRIALS study record update · 2023-03-23Blood Specimen Collection Study for NAFLD
-
CLINICAL_TRIALS study record update · 2023-01-06An Open-Label Study to Assess the Hepatic Protection Effect of a Food Supplement Product, SNP-612, in Patients With Non-alcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2023-01-06The European NAFLD Registry
-
CLINICAL_TRIALS study record update · 2022-09-16A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis
-
CLINICAL_TRIALS study record update · 2022-08-23Evaluation of Diagnostic Performances of a New Point-of-care Ultrasound System for the Detection of Fibrotic NASH and the Assessment of Liver Disease Severity in Patients With Known or Suspected Chronic Liver Disease
-
CLINICAL_TRIALS study record update · 2022-08-09Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912
-
CLINICAL_TRIALS study record update · 2022-08-04A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2022-07-15AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
-
CLINICAL_TRIALS study record update · 2022-07-05A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2022-07-01A Phase I, Two-part, Single and Optional Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 500 and 750 mg PXL770 in Healthy Subjects
-
CLINICAL_TRIALS study record update · 2022-06-14A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2022-05-24Effects of Exercise on VLDL-TG Metabolism in Individuals With NAFL and NASH
-
CLINICAL_TRIALS study record update · 2022-05-24Splanchnic and Systemic VLDL-TG and FFA Balance in Individuals With NAFL and NASH
-
CLINICAL_TRIALS study record update · 2022-03-18Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial
-
CLINICAL_TRIALS study record update · 2022-03-02An Open-Label, Single-Dose Pharmacokinetic Study of Liquid Subcutaneous Formulation of BIO89-100 in Subjects With Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis